NGNE vs. SYRE, MLYS, AVDL, PHVS, NRIX, ARDX, ORIC, PRAX, ZYME, and LENZ
Should you be buying Neurogene stock or one of its competitors? The main competitors of Neurogene include Spyre Therapeutics (SYRE), Mineralys Therapeutics (MLYS), Avadel Pharmaceuticals (AVDL), Pharvaris (PHVS), Nurix Therapeutics (NRIX), Ardelyx (ARDX), Oric Pharmaceuticals (ORIC), Praxis Precision Medicines (PRAX), Zymeworks (ZYME), and LENZ Therapeutics (LENZ). These companies are all part of the "pharmaceutical products" industry.
Neurogene vs. Its Competitors
Neurogene (NASDAQ:NGNE) and Spyre Therapeutics (NASDAQ:SYRE) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, dividends and earnings.
52.4% of Neurogene shares are held by institutional investors. Comparatively, 80.4% of Spyre Therapeutics shares are held by institutional investors. 11.6% of Neurogene shares are held by insiders. Comparatively, 6.2% of Spyre Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Neurogene currently has a consensus target price of $46.17, suggesting a potential upside of 127.37%. Spyre Therapeutics has a consensus target price of $53.40, suggesting a potential upside of 244.61%. Given Spyre Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Spyre Therapeutics is more favorable than Neurogene.
Neurogene has a beta of 1.51, meaning that its stock price is 51% more volatile than the S&P 500. Comparatively, Spyre Therapeutics has a beta of 2.68, meaning that its stock price is 168% more volatile than the S&P 500.
Neurogene has higher revenue and earnings than Spyre Therapeutics. Neurogene is trading at a lower price-to-earnings ratio than Spyre Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Neurogene had 6 more articles in the media than Spyre Therapeutics. MarketBeat recorded 8 mentions for Neurogene and 2 mentions for Spyre Therapeutics. Neurogene's average media sentiment score of 0.18 beat Spyre Therapeutics' score of 0.00 indicating that Neurogene is being referred to more favorably in the media.
Neurogene's return on equity of -36.16% beat Spyre Therapeutics' return on equity.
Summary
Spyre Therapeutics beats Neurogene on 8 of the 15 factors compared between the two stocks.
Get Neurogene News Delivered to You Automatically
Sign up to receive the latest news and ratings for NGNE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding NGNE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Neurogene Competitors List
Related Companies and Tools
This page (NASDAQ:NGNE) was last updated on 7/8/2025 by MarketBeat.com Staff
Free NGNE Stock Alerts